Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease

JAMA Neurology

Volumn 72, Issue 3, 2015, Pages 333-339

  Han, Pengcheng ^a   Caselli, Richard J ^b   Baxter, Leslie ^a   Serrano, Geidy ^c   Yin, Junxiang ^a   Beach, Thomas G ^c   Reiman, Eric M ^d   Shi, Jiong ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d BANNER ALZHEIMER S INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; ADCYAP1 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; AUDITORY VERBAL LEARNING TEST TOTAL LEARNING; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA ASSESSMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; JUDGMENT OF LINE ORIENTATION TEST; MALE; MATTIS DEMENTIA RATING SCALE SCORE; MENTAL DETERIORATION; MENTAL PERFORMANCE; MIDDLE TEMPORAL GYRUS; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SCORING SYSTEM; STRIATE CORTEX; STROOP TEST; SUPERIOR FRONTAL GYRUS; UPREGULATION; VERY ELDERLY; BRAIN; CEREBROSPINAL FLUID; CROSS-SECTIONAL STUDY; METABOLISM; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE;

EID: 84926353009     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.3625     Document Type: Article

References (23)

1. Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989;164(1):567-574.
2. Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61(3):283-357.
3. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 2000;52(2):269-324.
4. Han P, Liang W, Baxter LC, et al. Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease. Neurology. 2014;82(19):1724-1728.
5. Han P, Tang Z, Yin J, et al. Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity. Neurobiol Aging. 2014;35(9):2064-2071.
6. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56(10):1095-1097.
7. Petersen RC, Jack CR Jr. Imaging and biomarkers in early Alzheimer's disease and mild cognitive impairment. Clin Pharmacol Ther. 2009;86(4):438-441.
8. Petersen RC. Early diagnosis of Alzheimer's disease: is MCI too late? Curr Alzheimer Res. 2009;6(4):324-330.
9. Vemuri P, Wiste HJ, Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009;73(4):294-301.
10. Vemuri P, Wiste HJ, Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009;73(4):287-293.
11. Benson SW. The Foundations of Chemical Kinetics. New York, NY: McGraw-Hill Inc; 1960.
12. Filippi M, Agosta F. Structural and functional network connectivity breakdown in Alzheimer's disease studied with magnetic resonance imaging techniques. J Alzheimers Dis. 2011;24(3):455-474.
13. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155(3):853-862.
14. Li R, Lindholm K, Yang LB, et al. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2004;101(10):3632-3637.
15. Feany MB, Quinn WG. A neuropeptide gene defined by the Drosophila memory mutant amnesiac. Science. 1995;268(5212):869-873.
16. Pirger Z, Laszlo Z, Hiripi L, et al. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors are present and biochemically active in the central nervous system of the pond snail Lymnaea stagnalis. J Mol Neurosci. 2010;42(3):464-471.
17. Nonaka N, Farr SA, Nakamachi T, et al. Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins. Peptides. 2012;36(2):168-175.
18. Rat D, Schmitt U, Tippmann F, et al. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 2011; 25(9):3208-3218.
19. q, protein kinase C, and activation of Src. J Neurosci. 2005;25(49):11374-11384.
20. Michel S, Itri J, Han JH, Gniotczynski K, Colwell CS. Regulation of glutamatergic signalling by PACAP in the mammalian suprachiasmatic nucleus. BMC Neurosci. 2006;7:15.
21. He C, Chen F, Li B, Hu Z. Neurophysiology of HCN channels: from cellular functions to multiple regulations. Prog Neurobiol. 2014;112:1-23.
22. + currents and caspase activity in cultured adult mouse olfactory neurons. Neuroscience. 2005;134(3):745-756.
23. + current in adult mouse olfactory neuroepithelia. Neuroscience. 2006;138(2):411-419.